Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accidental, artifice, bid, blocker, CCPA, cessation, CoD, Codification, Corbin, custody, deadline, deletion, delist, delisted, delisting, deployment, drawn, eighteen, FCA, freestanding, GDPR, GMP, hacking, harbor, immaterial, inflated, influenzae, junior, KMJ, landscape, malware, mobile, network, Nomination, notification, obstructing, offense, opt, orexplore, OS, OTC, outbreak, pandemic, par, pari, passu, phishing, prejudice, prompted, pronouncement, PRSU, ransomware, reassessed, regain, residual, RSU, season, seasonality, sham, social, sophisticated, sophistication, stipulation, stricter, successor, Switzerland, tenant, theft, transmit, trick, trust, unlawful, VAT, Wainwright, wave, wholesale
Removed:
advanced, allocation, androgen, applied, approximate, assigned, avoid, Baltimore, Boston, chose, close, conceal, consummation, contemplated, converted, default, diagnostic, disposal, earliest, elimination, emerging, fourth, inclusion, Jumpstart, kind, landlord, Maryland, master, Mexico, objective, principally, ratio, receptor, retroactively, reward, rolling, safeguarding, simplification, sublease, sublicense, TKAI, UMB, unaudited, University, volume, York
Filing tables
Filing exhibits
ELDN similar filings
Filing view
External links
|
| Exhibit 23.2 |
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in Registration Statement Nos. 333-200413, 333-203032, 333-210058, 333-216432 and 333-232428 on Form S-8 and Registration Statement Nos. 333-218949 and 333-226286 on Form S-3 of our report dated March 16, 2020, relating to the consolidated financial statements of Novus Therapeutics, Inc., appearing in this Annual Report on Form 10-K of Novus Therapeutics, Inc. for the year ended December 31, 2019.
/s/ KMJ Corbin & Company LLP
Costa Mesa, California
March 16, 2020
|
|
|